{
    "pmcid": "9257560",
    "qa_pairs": {
        "How many nanobody clones were identified and characterized for their binding and neutralizing capabilities in the study?": [
            "Nine",
            "Eighteen",
            "Six",
            "Twelve"
        ],
        "What is the unique feature of the SARS-CoV-2 spike protein that is crucial for viral infectivity?": [
            "The furin cleavage site between the S1 and S2 domains",
            "The trimeric structure of the spike protein",
            "The presence of the receptor-binding domain (RBD) in the S1 subunit",
            "The ability to bind to the ACE2 receptor"
        ],
        "What makes the nanobodies developed in the study particularly valuable for ongoing surveillance and treatment efforts?": [
            "Their ability to detect and neutralize a broad range of SARS-CoV-2 variants",
            "Their large size and complex production process",
            "Their exclusive targeting of the S2 subunit of the spike protein",
            "Their reliance on human antibodies for effectiveness"
        ],
        "What method was used to reveal the binding of P86 and P17 to the spike protein in both up and down RBD conformations?": [
            "Cryo-electron microscopy (cryo-EM)",
            "X-ray crystallography",
            "Nuclear magnetic resonance (NMR) spectroscopy",
            "Surface plasmon resonance (SPR)"
        ],
        "Which nanobody clone targets conserved epitopes on the RBD and also contacts the N-terminal domain (NTD), allowing it to neutralize multiple VOCs including Omicron variants?": [
            "P86",
            "P17",
            "P12",
            "P34"
        ]
    }
}